Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749957 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis
A Phase 1 study, sponsored by Beacon Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00749957 is a Phase 1 study that has completed, run by Beacon Therapeutics. The registered enrollment target is 12 participants.
The verdict
NCT00749957, a Phase 1 study, has completed, sponsored by Beacon Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene. Funding Source - FDA OOPD
Interventions
- BIOLOGICAL rAAV2-CB-hRPE65
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2009-06-17 |
| Est. Completion | 2017-09-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749957
The ClinicalTrials.gov registry entry for NCT00749957 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beacon Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rAAV2-CB-hRPE65 is the first listed.
NCT00749957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749957 about?
NCT00749957 is a clinical study titled "Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis". The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene. Funding Source - FDA OOPD
What is the current status of trial NCT00749957?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2009-06-17. Estimated completion is 2017-09-22.
What interventions are being tested in trial NCT00749957?
The interventions under investigation include: rAAV2-CB-hRPE65 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00749957?
This trial is sponsored by Beacon Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.